Ratings by Cantor Fitzgerald (Alethia Young)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/11/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/8/2025 | Stoke Therapeutics | STOK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/5/2024 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | Stoke Therapeutics | STOK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2023 | Stoke Therapeutics | STOK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2023 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2023 | Spectrum Pharmaceuticals | SPPI | Maintain | Neutral (N/A) |
|
Details | ||
| 2/3/2023 | Spectrum Pharmaceuticals | SPPI | Maintain | Neutral (N/A) |
|
Details | ||
| 11/16/2022 | NexImmune Inc | NEXI | Downgrade | Neutral (Overweight) |
0.45 (3.93) |
773.33% | Details | |
| 11/3/2022 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2022 | Global Blood Therapeutics | GBT | Downgrade | Neutral (Overweight) |
63.84 (68.49) |
7.28% | Details | |
| 8/8/2022 | Aligos Therapeutics Inc. | ALGS | Downgrade | Neutral (Buy) |
1.39 (5.60) |
302.88% | Details | |
| 3/10/2022 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2022 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2021 | Arena Pharma | ARNA | Downgrade | Neutral (Overweight) |
91.80 (99.98) |
8.91% | Details | |
| 11/2/2021 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2021 | Theseus Pharmaceuticals Inc. | THRX | New Coverage | Overweight (N/A) |
17.12 (4.06) |
-76.29% | Details | |
| 10/14/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/17/2021 | Spectrum Pharmaceuticals | SPPI | Maintain | Neutral (N/A) |
|
Details | ||
| 7/23/2021 | Adverum Biotechnologies | ADVM | Downgrade | Neutral (Overweight) |
3.15 (4.36) |
38.41% | Details | |
| 6/14/2021 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2021 | Longboard Pharmaceuticals Inc | LBPH | New Coverage | Overweight (N/A) |
16.67 (59.98) |
259.81% | Details | |
| 3/23/2021 | Eledon Pharamceuticals | ELDN | New Coverage | Overweight (N/A) |
14.46 (3.92) |
-72.89% | Details | |
| 3/17/2021 | Nkarta Inc. | NKTX | New Coverage | Overweight (N/A) |
47.86 (2.79) |
-94.17% | Details | |
| 3/9/2021 | NexImmune Inc | NEXI | New Coverage | Overweight (N/A) |
20.63 (3.93) |
-80.95% | Details | |
| 10/23/2020 | Stoke Therapeutics | STOK | New Coverage | Overweight (N/A) |
37.97 (33.00) |
-13.09% | Details | |
| 10/19/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2020 | MyoKardia | MYOK | Downgrade | Neutral (Overweight) |
139.60 (224.91) |
61.11% | Details | |
| 10/5/2020 | Regeneron Pharma | REGN | Upgrade | Overweight (Neutral) |
564.80 (629.69) |
11.49% | Details | |
| 8/13/2020 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/24/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/30/2020 | Intercept Pharmaceuticals | ICPT | Downgrade | Neutral (Overweight) |
77.49 (19.00) |
-75.48% | Details | |
| 6/2/2020 | Arena Pharma | ARNA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2020 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/20/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2020 | Aurinia Pharmaceuticals | AUPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2020 | Puma Biotechnology | PBYI | Maintain | Neutral (N/A) |
|
Details | ||
| 5/8/2020 | Arena Pharma | ARNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2020 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2020 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2020 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2020 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/8/2020 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/7/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2020 | Arcus Biosciences | RCUS | New Coverage | Overweight (N/A) |
13.97 (31.64) |
126.49% | Details | |
| 3/27/2020 | Stemline Therapeutics | STML | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2020 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2020 | Aurinia Pharmaceuticals | AUPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2020 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2020 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2020 | Adverum Biotechnologies | ADVM | Upgrade | Overweight (Neutral) |
10.94 (4.36) |
-60.15% | Details | |
| 2/6/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2020 | Provention Bio Inc. | PRVB | New Coverage | Overweight (N/A) |
16.52 (24.98) |
51.21% | Details | |
| 1/23/2020 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/26/2019 | Spectrum Pharmaceuticals | SPPI | Downgrade | Neutral (Overweight) |
8.75 (1.03) |
-88.23% | Details | |
| 12/18/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/5/2019 | Aurinia Pharmaceuticals | AUPH | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2019 | Global Blood Therapeutics | GBT | New Coverage | Overweight (N/A) |
56.14 (68.49) |
22% | Details | |
| 11/21/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2019 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2019 | Puma Biotechnology | PBYI | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2019 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2019 | Amgen | AMGN | Upgrade | Overweight (Neutral) |
214.41 (360.84) |
68.29% | Details | |
| 10/23/2019 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 9/30/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/9/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/9/2019 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/5/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/29/2019 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/25/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2019 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2019 | Puma Biotechnology | PBYI | Downgrade | Neutral (Overweight) |
30.02 (8.21) |
-72.65% | Details | |
| 4/11/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/5/2019 | Celgene | CELG | Downgrade | Neutral (Overweight) |
93.85 (108.24) |
15.33% | Details | |
| 3/29/2019 | TG Therapeutics | TGTX | New Coverage | Overweight (N/A) |
7.22 (56.00) |
675.62% | Details | |
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Overweight) |
320.59 (214.80) |
-33% | Details | |
| 3/19/2019 | Puma Biotechnology | PBYI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2019 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2019 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/7/2019 | Spectrum Pharmaceuticals | SPPI | New Coverage | Overweight (N/A) |
11.12 (8.75) |
-21.31% | Details | |
| 1/30/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2019 | Ascendis Pharma | ASND | New Coverage | Overweight () |
73.65 (264.04) |
258.51% | Details | |
| 12/6/2018 | Tesaro | TSRO | Downgrade | Neutral (Overweight) |
73.69 (74.96) |
1.72% | Details | |
| 11/12/2018 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/26/2018 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2018 | Tesaro | TSRO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/22/2018 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/1/2018 | Alnylam Pharmaceuticals | ALNY | New Coverage | Overweight (N/A) |
90.09 (299.17) |
232.08% | Details | |
| 10/1/2018 | MyoKardia | MYOK | New Coverage | Overweight (N/A) |
64.60 (139.60) |
116.1% | Details | |
| 10/1/2018 | Celgene | CELG | New Coverage | Overweight (N/A) |
89.25 (93.85) |
5.15% | Details | |
| 10/1/2018 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
97.97 (57.04) |
-41.78% | Details | |
| 10/1/2018 | Regeneron Pharma | REGN | New Coverage | Neutral (N/A) |
406.00 (629.69) |
55.1% | Details | |
| 10/1/2018 | Puma Biotechnology | PBYI | New Coverage | Overweight (N/A) |
45.80 (30.02) |
-34.45% | Details | |
| 10/1/2018 | Incyte | INCY | New Coverage | Neutral (N/A) |
69.04 (114.42) |
65.73% | Details | |
| 10/1/2018 | Vertex | VRTX | New Coverage | Overweight (N/A) |
189.74 (498.17) |
162.55% | Details | |
| 10/1/2018 | Amgen | AMGN | New Coverage | Neutral (N/A) |
208.89 (214.41) |
2.64% | Details | |
| 10/1/2018 | Intercept Pharmaceuticals | ICPT | New Coverage | Overweight (Neutral) |
127.55 (19.00) |
-85.1% | Details | |
| 10/1/2018 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
47.06 (81.65) |
73.5% | Details | |
| 10/1/2018 | Gilead Sciences | GILD | New Coverage | Overweight (N/A) |
76.58 (125.82) |
64.3% | Details | |
| 10/1/2018 | Biogen | BIIB | New Coverage | Overweight (Neutral) |
355.60 (214.80) |
-39.6% | Details | |
| 10/1/2018 | Tesaro | TSRO | New Coverage | Overweight (N/A) |
38.41 (73.69) |
91.85% | Details | |
| 10/1/2018 | Sarepta Therapeutics | SRPT | New Coverage | Overweight (N/A) |
159.25 (82.56) |
-48.16% | Details |
